{"id":497,"date":"2026-09-06T21:48:14","date_gmt":"2026-09-06T21:48:14","guid":{"rendered":"https:\/\/premiumpeptide.shop\/research\/compounds\/tirzepatid\/"},"modified":"2026-09-06T21:59:41","modified_gmt":"2026-09-06T21:59:41","slug":"tirzepatid","status":"publish","type":"page","link":"https:\/\/premiumpeptide.shop\/en\/research\/compounds\/tirzepatid\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"

Tirzepatide is an acylated peptide analogue with a dual receptor profile. For the analysis, the differentiation from structurally related analogues is above all decisive.<\/p>\n

What is tirzepatide?<\/h2>\n

Tirzepatide is a peptide of 39 amino acids whose sequence is derived from GIP and contains elements that also mediate activity at the GLP-1 receptor. The structure contains two aminoisobutyric acid residues, an amidated C-terminal end and a C20 diacid bound to a lysine via two AEEA spacers. The average molecular mass is approximately 4,814 Da.<\/p>\n

As with other acylated analogues, chemically this is a lipopeptide conjugate, not a simple peptide.<\/p>\n

Research context<\/h2>\n

Tirzepatide is described in the scientific literature as a dual receptor agonist. Compounds of this class listed in the catalogue are exclusively reference and research material and are not intended for use in humans or animals. This page makes no statements about effect, indication or application. Analytically relevant is the proximity to other long-chain acylated analogues: the molecules differ in sequence length, fatty acid chain and number of spacers, but are similar in chromatography and UV behaviour.<\/p>\n

Analytical identification<\/h2>\n